Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES
COLESTIPOL HYDROCHLORIDE GRANULES FOR ORAL SUSPENSION
Authorized Generic of COLESTID® (colestipol hydrochloride granule, for suspension)

PEAPACK, NJ, January 2016—Greenstone LLC, a US-based subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Colestipol Hydrochloride Granules for Oral Suspension to its ever-expanding generic pharmaceutical product line. The product is offered and available in cartons of 30 foils of 5 grams each, cartons of 90 foils of 5 grams each, and bottles of 500 grams with scoop.

Greenstone’s Colestipol Hydrochloride Granules for Oral Suspension is the authorized generic of, and equivalent to the innovator’s product, COLESTID® (colestipol hydrochloride granule, for suspension). This new authorized generic adds to Greenstone’s consistently growing line of products and is backed by the distribution and customer service support of Pfizer Inc., one of the world’s premiere biopharmaceutical companies. As a subsidiary of Pfizer Inc., Greenstone operates under the same values and commitment to bring quality pharmaceutical products to customers, payers, and the patients it serves.

See the Full Prescribing Information for Greenstone’s Colestipol Hydrochloride Granules for Oral Suspension at http://www.greenstonellc.com/product-list.aspx.

For more information about Greenstone LLC and its products, visit http://greenstonellc.com.

Colestid is a registered trademark of Pharmacia & Upjohn Company LLC.